Suppr超能文献

新型细菌 DNA 拓扑异构酶/拓扑异构酶 IV 抑制剂 CUO246 的性质。

and Properties of CUO246, a Novel Bacterial DNA Gyrase/Topoisomerase IV Inhibitor.

机构信息

Novartis Institutes for BioMedical Research, Emeryville, California, USA.

出版信息

Antimicrob Agents Chemother. 2022 Dec 20;66(12):e0092122. doi: 10.1128/aac.00921-22. Epub 2022 Nov 30.

Abstract

CUO246, a novel DNA gyrase/topoisomerase IV inhibitor, is active against a broad range of Gram-positive, fastidious Gram-negative, and atypical bacterial pathogens and retains activity against quinolone-resistant strains in circulation. The frequency of selection for single step mutants of wild-type S. aureus with reduced susceptibility to CUO246 was <4.64 × 10 at 4× and 8× MIC and remained low when using an isogenic QRDR mutant (<5.24 × 10 at 4× and 8× MIC). Biochemical assays indicated that CUO246 had potent inhibitory activity against both DNA gyrase (GyrAB) and topoisomerase IV (ParCE). Furthermore, CUO246 showed rapid bactericidal activity in time-kill assays and potent efficacy against S. aureus in a neutropenic murine thigh infection model. These results suggest that CUO246 may be useful in treating infections by various causative agents of acute skin and skin structure infections, respiratory tract infections, and sexually transmitted infections.

摘要

CUO246 是一种新型的 DNA 拓扑异构酶/拓扑异构酶 IV 抑制剂,对广泛的革兰氏阳性、苛养革兰氏阴性和非典型细菌病原体具有活性,并保留对循环中喹诺酮耐药株的活性。对野生型金黄色葡萄球菌的单步突变体的选择频率较低,对 CUO246 的敏感性降低,在 4×和 8×MIC 时<4.64×10,当使用同源 QRDR 突变体时,频率仍然较低(<5.24×10 在 4×和 8×MIC)。生化分析表明,CUO246 对 DNA 拓扑异构酶(GyrAB)和拓扑异构酶 IV(ParCE)均具有很强的抑制活性。此外,CUO246 在时间杀伤试验中表现出快速杀菌活性,并在中性粒细胞减少症小鼠大腿感染模型中对金黄色葡萄球菌表现出强大的疗效。这些结果表明,CUO246 可能对治疗各种急性皮肤和皮肤结构感染、呼吸道感染和性传播感染的病原体引起的感染有用。

相似文献

1
and Properties of CUO246, a Novel Bacterial DNA Gyrase/Topoisomerase IV Inhibitor.
Antimicrob Agents Chemother. 2022 Dec 20;66(12):e0092122. doi: 10.1128/aac.00921-22. Epub 2022 Nov 30.
2
Dual targeting of DNA gyrase and topoisomerase IV: target interactions of heteroaryl isothiazolones in Staphylococcus aureus.
Antimicrob Agents Chemother. 2007 Jul;51(7):2445-53. doi: 10.1128/AAC.00158-07. Epub 2007 May 14.
3
Dual targeting of DNA gyrase and topoisomerase IV: target interactions of garenoxacin (BMS-284756, T-3811ME), a new desfluoroquinolone.
Antimicrob Agents Chemother. 2002 Nov;46(11):3370-80. doi: 10.1128/AAC.46.11.3370-3380.2002.
5
Inhibition of DNA gyrase and DNA topoisomerase IV of Staphylococcus aureus and Escherichia coli by aminocoumarin antibiotics.
J Antimicrob Chemother. 2011 Sep;66(9):2061-9. doi: 10.1093/jac/dkr247. Epub 2011 Jun 21.
6
Target specificity of the new fluoroquinolone besifloxacin in Streptococcus pneumoniae, Staphylococcus aureus and Escherichia coli.
J Antimicrob Chemother. 2009 Mar;63(3):443-50. doi: 10.1093/jac/dkn528. Epub 2009 Jan 15.
7
Inhibition of Neisseria gonorrhoeae Type II Topoisomerases by the Novel Spiropyrimidinetrione AZD0914.
J Biol Chem. 2015 Aug 21;290(34):20984-20994. doi: 10.1074/jbc.M115.663534. Epub 2015 Jul 6.
8
Novel fluorobenzothiazole as a dual inhibitor of gyrase B and topoisomerase IV against Gram-positive pathogens.
Future Microbiol. 2023 Jul;18:625-638. doi: 10.2217/fmb-2022-0207. Epub 2023 Jun 22.
9
In vitro biological evaluation of novel broad-spectrum isothiazolone inhibitors of bacterial type II topoisomerases.
J Antimicrob Chemother. 2016 Oct;71(10):2831-9. doi: 10.1093/jac/dkw228. Epub 2016 Jun 26.
10
Antibacterial activity of novel dual bacterial DNA type II topoisomerase inhibitors.
PLoS One. 2020 Feb 19;15(2):e0228509. doi: 10.1371/journal.pone.0228509. eCollection 2020.

引用本文的文献

本文引用的文献

2
Topoisomerase Inhibitors Addressing Fluoroquinolone Resistance in Gram-Negative Bacteria.
J Med Chem. 2020 Jul 23;63(14):7773-7816. doi: 10.1021/acs.jmedchem.0c00347. Epub 2020 Jul 7.
3
Novel Bacterial Topoisomerase Inhibitors with Potent Broad-Spectrum Activity against Drug-Resistant Bacteria.
Antimicrob Agents Chemother. 2017 Apr 24;61(5). doi: 10.1128/AAC.02100-16. Print 2017 May.
5
Biological profiling of novel tricyclic inhibitors of bacterial DNA gyrase and topoisomerase IV.
J Antimicrob Chemother. 2016 Jul;71(7):1905-13. doi: 10.1093/jac/dkw061. Epub 2016 Mar 30.
7
Linezolid Surveillance Results for the United States (LEADER Surveillance Program 2014).
Antimicrob Agents Chemother. 2016 Mar 25;60(4):2273-80. doi: 10.1128/AAC.02803-15. Print 2016 Apr.
10
Renaissance of antibiotics against difficult infections: Focus on oritavancin and new ketolides and quinolones.
Ann Med. 2014 Nov;46(7):512-29. doi: 10.3109/07853890.2014.935470. Epub 2014 Jul 24.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验